Floatz logo

(1S,2S)-(+)-PSEUDOEPHEDRINE

SHY-DRAGER SYNDROME

Vanderbilt UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the SHY-DRAGER SYNDROME cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
IOFLUPANE
GE Healthcare
Phase 3B
ATH-434
Alterity Therapeutics
Phase 2B
Riluzole
King's College London
Phase 3B

View all 40 →

Same molecule, other indications

(1S,2S)-(+)-PSEUDOEPHEDRINE is also rated in:

sinusitisDormant
BB
Indicative ·
69 / 100
View asset →
migraine disorderDormant
B
Indicative ·
62 / 100
View asset →
pure autonomic failureDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →